The novel coronavirus disease (COVID-19) is associated with a high incidence of
coagulopathy and venous thromboembolism that may contribute to the worsening of the …

Thromboprophylaxis in hospitalized patients with COVID-19 has been associated with a
survival benefit and is strongly recommended. However, the optimal dose of …

Background COVID-19 is a respiratory disease that results in a prothrombotic state
manifesting as thrombotic, microthrombotic and thromboembolic events. As a result, several …

Abstract Background and Objective Low-dose acetylsalicylic acid (ASA, aspirin) is a well-
known and frequently studied drug for primary and secondary prevention of disease due to …

Objetivo Caracterización de una muestra de pacientes hospitalizados por complicaciones
de la infección COVID-19 con atención a potenciales determinantes pronósticos de su …

It has been well established in the literature that those with COVID-19 are at increased risk
of thrombotic disease, however, research into the best modalities to therapeutically anti …

Introduction The risk of mortality in patients with COVID-19 was found to be significantly
higher in patients who experienced thromboembolic events. Thus, several guidelines …

Background Studies have indicated that hospitalized COVID-19 patients benefit from
anticoagulation therapy in terms of survival; however, there is an ongoing controversy over …

Anticoagulant therapy becomes critical to preventing further complications caused by the
hypercoagulative state in COVID-19 patients. The optimal dose and time-dependent …

Background COVID-19 is a respiratory disease that results in a prothrombotic state
manifesting as thrombotic, microthrombotic and thromboembolic events. As a result, several …